English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Standard first line therapy for elderly patients (over 65 years) with DLCL is CHOP or CHOP alike, anthracycline-containing regimens. Due to cardiac comorbidity and absence of confident tool for prediction of anthracycline induced cardiac toxicity (early as well as late) there is a need for safer and more effective chemotherapy regimens. This interim phase II study is a single center experience with non-anthracycline regimen compared with CHOP regimen. Over past 3 years 24 patients with DLCL in advanced stages, aged over 65 years, were randomized to receive either standard CHOP regimen or BOCAD (Bleomycin 15 mg day 1, Oncovin 2 mg day 1, Actinomycin D 1 days 2 and 4, Deticene 200 mg days 3 and 5, Pronison day 2-7, CCNU 40 mg) in four-week period. Eleven patients were included in the CHOP group with median age 69 years (range, 67-79 years) in stage II and higher, 4 patients with bulky disease and 3 in clinical stage IV; 2 with performance status 2, four of them with one comorbid disease. Thirteen patients were included in BOCAD group of median age 75 years (range, 67-81 years) in stage IIIA and higher, 4 with bulky disease and 6 in clinical stage IV, with 5 patients in performance status 2, nine of them with one or more comorbid disease. In CHOP group RR was 65% (4 CR + 2 PR) with time to progresion (TTP) 16 months (4 still alive), in the BOCAD group RR was 33% (2 CR+1 PR) with TTP 3 months (1 still alive). Proportion test didn't showed statistically significant difference in RR, but significant difference between TTP in two group (P=0.02) by KaplanMeier test. Proportion test showed statistically significant difference (P=0.04) for RR in the BOCAD group between group of patients with comorbidity and without comorbidity. In the CHOP group there is no statistical differences between patients with comorbidity and without comorbidity. Differences in PS did not show any statistically significant difference in RR and TTP. Our preliminary results showed that comorbidity might influence therapeutic response. Regarding comparison of efficacy between two groups, further investigation is needed. Zoran TOMA©EVIÆ Svetislav JELIÆ Nenad MILANOVIÆ Du1an RISTIÆ Mirjana MIHAILOVIÆ Anðela KARAFERIÆ

CHOP VS. BOCAD in elderly patients with diffuse large cell lymphoma (DLCL): Preliminary results